Some shareholders think they were shafted in the multi-billion dollar deal between Sepracor and Dainippon Sumitomo Pharma. They're so miffed, in fact, that they've filed a lawsuit stating that the amount offered undervalues the company and its shares.
Sepracor shareholders are voicing their concern over the company’s proposed $2.6 billion sale to Dainippon Sumitomo Pharma in a lawsuit filed yesterday in Delaware.
Less than one week after announcing the deal between the Japanese firms, investors are calling the price negotiated-$23 per share in cash-inadequate and unfair. Sepracor, however, insists that the offer price represents a 48 percent premium over the stock’s six-month average price, and a 27.6 percent premium over the closing price of Sepracor’s common stock as of September 1.
Credit Suisse analyst Scott Hirsch stated in a letter to investors that while Sepracor’s sales are close to $400 million a year, its dwindling development pipeline (mostly respiratory and central nervous system treatments) doesn’t make the company appealing to a large number of buyers.
“In our view, if a US firm wanted Sepracor, that likely would’ve happened already, as there have been plenty of lookers over the years,’’ Hirsch stated. “We think Dainippon Sumitomo is more interested in the sales platform and operating leverage than the revenue stream.’’
The two investors filing the suit claim that Sepracor didn’t leave much room for negotiating after the bid was made. They noted the inclusion of a $77.4 million termination fee and a “no solicitation” provision giving Dainaippon first chance to counter other offers. The complaint also states that Sepracor “did not undertake to canvas the market prior to entering into the proposed merger, and thus failed to inform themselves of the inherent fair value of the company.”
Sepracor could not be reached for comment by deadline.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.
2 Commerce Drive
Cranbury, NJ 08512